Transgene : Premiers résultats positifs de TG6002 en clinique
>Des premiers résultats positifs - TNG publiait hier soir ses premiers résultats cliniques sur son candidat médicament TG6002. Ces premiers résultats de phase I se révèlent positifs confirmant une bonne tolérance et des premiers signes des fonctionnalités du produit.On parle ici d’un actif ne venant pas directement de la plateforme InvirIO mais dont le concept est proche. Le principe correspond à l’administration d’un virus modifié qui cible directement la tumeur...Transgene is a biopharmaceutical company that designs and develops immunotherapy and virotherapy products for the treatment of cancers and infectious diseases. Co. is developing three anti-cancer products that are in clinical trials: (cancer of the lungs, liver and oropharynx); two anti-infectious immunotherapy products also in clinical trials: (hepatitis B and C). Co. also has products in the pre-clinical development stage. Co. operates in a single business segment, the research and development of therapeutic vaccines and immunotherapy products. Co. does not have any products on the market. Substantially all of its operations are conducted in France.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.